PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Regulation FD Disclosure

52

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Regulation FD Disclosure

Item7.01.

Regulation FD Disclosure.

On March20, 2017, Provectus Biopharmaceuticals, Inc. (the
Company) issued a press release (the Press Release) announcing
that it entered into an exclusive Definitive Financing Commitment
Term Sheet with a group of the Companys stockholders related to a
previously submitted unsolicited proposal. The Company also
announced the termination of the Companys rights offering,
without accepting any funds from investors. A copy of the Press
Release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.

to the rules and regulations of the Commission, the information
in this Item 7.01 disclosure, including Exhibit 99.1 and
information set forth therein, is deemed to have been furnished
and shall not be deemed to be filed under the Securities Exchange
Act of 1934, as amended.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1 Press Release, dated March20, 2017

2


About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Recent Trading Information

PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) closed its last trading session up +0.0001 at 0.0300 with 1,506,243 shares trading hands.

An ad to help with our costs